NCT07005024 2026-02-05
DOAC
University of Vermont
Phase 3 Recruiting
Clinical Trials
31 trialsNCT06940570 2025-10-23
MATCH
University of Texas Southwestern Medical Center
Phase 3 Suspended
NCT05029063 2025-07-09
TRIM-Line
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT03837171 2024-06-25
TRANSPORT
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT05704894 2023-01-30
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Blau Farmaceutica S.A.
Phase 3 Unknown
NCT02583191 2021-05-03
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH
Phase 3 Terminated
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02555878 2019-09-12
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Janssen Research & Development, LLC
Phase 3 Completed
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT03003273 2019-02-01
DALFEN
All India Institute of Medical Sciences
Phase 3 Terminated
NCT02746185 2018-08-13
CASTA-DIVA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00236951 2018-02-20
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
American Regent, Inc.
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01164046 2014-12-03
Longheva
University Medical Center Groningen
Phase 3 Terminated
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00694382 2013-01-23
SAVE-ONCO
Sanofi
Phase 3 Completed
NCT01343680 2012-05-30
Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
Alberta Children's Hospital
Phase 3 Terminated
NCT00210587 2011-06-10
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00341055 2011-06-10
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00261677 2011-05-23
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Ortho Biotech Products, L.P.
Phase 3 Completed
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00270101 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270127 2011-05-18
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270166 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00115167 2009-05-11
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
Amgen
Phase 3 Completed
NCT00111137 2008-02-28
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 3 Completed
NCT00145652 2007-07-30
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
Sundsvall Hospital
Phase 3 Completed
NCT00037791 2006-11-09
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Pfizer
Phase 3 Completed